| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_681410d7ab3b102e65aba7e136325807
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_333a87fa0e8614831ee840e81e85d718
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72506b00510ebc9c9a5b4c1f794e4ada
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_580da6d76866a123e2418f31b0181ead
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf1886fbf2d43e52aa894bc98f82e5dc |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19 |
| filingDate |
2005-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b54dff9b4ae5a1b695fa1f82dc801162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f2c21a34b266fee33fcb772bb5bd368
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f40a5dd67b87a2bb99f745ad87910ae7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_385322906e23e0249879cf898a81dd96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5493ec70024ec3d3e26e2bde967f4d8a |
| publicationDate |
2006-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006252830-A1 |
| titleOfInvention |
Method for the treatment of magnesium and potassium deficiencies |
| abstract |
A method for the treatment of depleted intracellular and serum magnesium levels by administration of a highly bioavailable magnesium salt is disclosed. A prescription dispensing system is also disclosed. The highly bioavailable magnesium salt can be administered alone or as adjunctive therapy in conjunction with various medications that cause or exacerbate depleted intracellular magnesium levels, such as renal magnesium wasting medications, including diuretics, immunosuppressants, chemotherapeutic agents, and antibiotics. The highly bioavailable magnesium salt can also be used as adjunctive therapy in conjunction with Class III anti-arrhythmic drugs to attenuate the QTc interval and reduce the risk of fatal arrhythmias, which are a common risk associated with Class III anti-arrhythmic drugs. The administration of a highly bioavailable magnesium salt in accordance with the present invention also serves to restore intracellular potassium levels to normal ranges in patients who remain hypokalemic despite potassium therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008033755-A1 |
| priorityDate |
2005-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |